A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the ability of oral triamcinalone given
twice a day to patients with androgen independent prostate cancer to produce a sustained
biochemical response. Secondary goals are to describe the safety and tolerability at this
dose and schedule, to determine the time to sustained biochemical response, to determine the
duration of biochemical response, to determine the time to disease progression.